Contineum Therapeutics, Inc. officer Daniel Lorrain filed a Form 144 notice on November 4, 2026, disclosing a proposed sale of 4,170 shares of common stock on NASDAQ under a Rule 10b5-1 plan.

Key Highlights

  • Proposed sale: Daniel Lorrain, an officer of Contineum Therapeutics, Inc., intends to sell 4,170 shares of common stock with an aggregate market value of $40,407.30.
  • Acquisition origin: The shares were acquired on May 9, 2017, through Restricted Stock Units granted by the issuer.
  • Approximate sale date: The filing lists November 4, 2026 as the approximate date of sale, to be executed through Morgan Stanley Smith Barney LLC Executive Financial Services.
  • 10b5-1 plan: The sale is conducted under a Rule 10b5-1 plan adopted on September 23, 2025.
  • Prior sales in past 3 months: Lorrain sold 4,170 shares on October 1, 2026 for gross proceeds of $53,883.91, and 9,520 shares on September 1, 2026 for gross proceeds of $154,895.52, both under 10b5-1 plans.
  • Shares outstanding: The filing reports 35,353,313 shares of common stock outstanding.

Lorrain's Proposed Sale and Recent Transaction History at Contineum Therapeutics

According to the Form 144 filing submitted to the SEC, Daniel Lorrain, identified as an officer of Contineum Therapeutics, Inc. (NASDAQ:CTNM), intends to sell 4,170 shares of the company's common stock. The aggregate market value of the proposed sale is listed as $40,407.30. The shares are to be sold through Morgan Stanley Smith Barney LLC Executive Financial Services, located at 1 New York Plaza, 8th Floor, New York, NY 10004, on NASDAQ.

The filing discloses that the 4,170 shares subject to the proposed sale were acquired on May 9, 2017, through Restricted Stock Units issued by the company. The notice indicates the sale is planned for approximately November 4, 2026, and is being conducted pursuant to a Rule 10b5-1 trading plan that Lorrain adopted on September 23, 2025. The filing notes that 35,353,313 shares of common stock were outstanding at the time of the notice.

As required by Form 144, Lorrain also disclosed sales made during the prior three months. On October 1, 2026, he sold 4,170 shares under a 10b5-1 plan for gross proceeds of $53,883.91. On September 1, 2026, he sold 9,520 shares under a 10b5-1 plan for gross proceeds of $154,895.52. All sales listed in the filing are attributed to 10b5-1 plans for Daniel Lorrain at the company's address of 3565 General Atomics Court, Suite 200, San Diego, California 92121.

What Was Disclosed

Contineum Therapeutics officer Daniel Lorrain filed a Form 144 notice proposing the sale of 4,170 common shares valued at $40,407.30, to be executed under a 10b5-1 plan adopted September 23, 2025, along with disclosures of two prior sales totaling 13,690 shares in the previous three months.